These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 11792227)
21. Improving the management of patients after myocardial infarction, from admission to discharge. Amin A Clin Ther; 2006 Oct; 28(10):1509-39. PubMed ID: 17157110 [TBL] [Abstract][Full Text] [Related]
22. API expert consensus document on management of ischemic heart disease. Association of Physicians of India J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697 [TBL] [Abstract][Full Text] [Related]
23. The role of in-hospital initiation of cardiovascular protective therapies to improve treatment rates and clinical outcomes. Fonarow GC Rev Cardiovasc Med; 2003; 4 Suppl 3():S37-46. PubMed ID: 14564233 [TBL] [Abstract][Full Text] [Related]
25. Secondary prevention after acute myocardial infarction and coronary revascularisation: focus on Angiotensin converting enzyme inhibitors. Kaski JC; Fernandez-Berges D Cardiovasc Drugs Ther; 2008 Jun; 22(3):185-91. PubMed ID: 18317916 [TBL] [Abstract][Full Text] [Related]
26. Clinical aspects of left ventricular diastolic function assessed by Doppler echocardiography following acute myocardial infarction. Poulsen SH Dan Med Bull; 2001 Nov; 48(4):199-210. PubMed ID: 11767125 [TBL] [Abstract][Full Text] [Related]
27. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial. Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA; Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009 [TBL] [Abstract][Full Text] [Related]
28. Can antiarrhythmic drugs survive survival trials? Pratt CM; Waldo AL; Camm AJ Am J Cardiol; 1998 Mar; 81(6A):24D-34D. PubMed ID: 9537220 [TBL] [Abstract][Full Text] [Related]
29. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA; Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343 [TBL] [Abstract][Full Text] [Related]
30. [The changing prognosis of myocardial infarction in the reperfusion era: implications for evaluation and management of ventricular arrhythmias]. Gersh BJ Rev Esp Cardiol; 2003 Jun; 56(6):535-42. PubMed ID: 12783727 [TBL] [Abstract][Full Text] [Related]
31. Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients. Zuanetti G; Latini R J Diabetes Complications; 1997; 11(2):131-6. PubMed ID: 9101399 [TBL] [Abstract][Full Text] [Related]
32. Cardiovascular outcomes among elderly patients with heart failure and coronary artery disease and without atrial fibrillation: a retrospective cohort study. Zhao Q; Wang L; Kurlansky PA; Schein J; Baser O; Berger JS BMC Cardiovasc Disord; 2019 Jan; 19(1):19. PubMed ID: 30646855 [TBL] [Abstract][Full Text] [Related]
33. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. Shlipak MG; Browner WS; Noguchi H; Massie B; Frances CD; McClellan M Am J Med; 2001 Apr; 110(6):425-33. PubMed ID: 11331052 [TBL] [Abstract][Full Text] [Related]
34. Association of medical noncompliance and long-term adverse outcomes, after myocardial infarction in a minority and uninsured population. Amin AP; Mukhopadhyay E; Nathan S; Napan S; Kelly RF Transl Res; 2009 Aug; 154(2):78-89. PubMed ID: 19595439 [TBL] [Abstract][Full Text] [Related]
35. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338 [TBL] [Abstract][Full Text] [Related]
36. Summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease. White CM; Greene L J Manag Care Pharm; 2011 Jun; 17(5 Suppl):S1-15. PubMed ID: 21780334 [TBL] [Abstract][Full Text] [Related]
37. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention. Byun JK; Choi BG; Rha SW; Choi SY; Jeong MH; Atherosclerosis; 2018 Oct; 277():130-135. PubMed ID: 30212681 [TBL] [Abstract][Full Text] [Related]
38. Predictors and Impact of In-Hospital Recurrent Myocardial Infarction in Patients With Acute Coronary Syndrome: Findings From Gulf RACE-2. Al Saleh AS; Alhabib KF; Alsheik-Ali AA; Sulaiman K; Alfaleh H; Alsaif S; Al Mahmeed W; Asaad N; Amin H; Al-Motarreb A; Al Suwaidi J; Hersi AS Angiology; 2017 Jul; 68(6):508-512. PubMed ID: 27784731 [TBL] [Abstract][Full Text] [Related]